Zacks Investment Research · Dec 22, 2022
3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
AB
NASDAQ · ABMD
Abiomed, Inc.
Healthcare · Medical - Devices
$381.02
Up+$0.00 (+0.00%)
Updated Sep 11, 2026, 7:49 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 17.18B
- P/E ratio
- 126.85
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 15.7M
- Avg. volume
- 1.7M
Price performance
ABMD price history
1M range · 0 trading sessions · Daily adjusted prices
ABMD does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest ABMD news
The latest Smart Investors Daily articles mentioning ABMD.
Stock researchCompany · Overview
ABMD research
Overview
Company profile and research snapshot.
Company profile
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 2, 2022 | Morgan Stanley | Equal-Weight | — |
| Nov 2, 2022 | Deutsche Bank | Hold | — |
| Nov 1, 2022 | William Blair | Market Perform | — |
| Nov 1, 2022 | Piper Sandler | Neutral | — |
| Oct 13, 2022 | Mizuho | Buy | — |
News briefing
No generated briefing is available yet.
The Motley Fool · Dec 21, 2022
The Best Stocks to Invest $20,000 in Right Now
The investments you make now could power your portfolio returns for years to come.
The Motley Fool · Dec 16, 2022
Warren Buffett Loves These Stocks. Should You Buy Them Before 2023?
There's a lot more ahead for these market giants.
Benzinga · Dec 14, 2022
Pfizer, Novartis Are Among Overbought Healthcare Stocks: Are They Worth A Look?
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies. Here’s the latest list of major overbought players in this sector, with an RSI above or near 70. Novartis AG (NYSE: NVS) Novartis AG (NYSE: NVS) announced detailed results from the pivotal Phase 3 APPLY-PNH trial. The company’s stock has a 52-week high of $94.26 . RSI Value: 71.29 NVS Price Action: Shares of Novartis rose 0.4% to settle at $91.21 on Tuesday, and gained 0.4% in the pre-market trading session on Wednesday. Novo Nordisk A/S (NYSE: NVO) Novo Nordiskwill roll out its obesity ...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
